BID and leukemia: Additionally, we demonstrate the therapeutic potential of tBID‐mediated MOMP in venetoclax‐resistant Nalm6 leukaemia cells lacking active BAX and BAK, in which TRAIL treatment efficiently induces BID‐dependent apoptosis.